Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
Claus Garbe(University of Tübingen), John M. Kirkwood(UPMC Hillman Cancer Center), Axel Hauschild(University Hospital Schleswig-Holstein), Thomas Eigentler(University Children's Hospital Tübingen), Ulrich Keilholz(German Cancer Research Center)
Cited by 579
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k